Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review

References

• Polk A, Svane I-M, Andersson M, Nielsen D. Checkpoint inhibitors in breast cancer–current status. Cancer Treat Rev. 2018;63:122–134. doi:10.1016/j.ctrv.2017.12.008
   PubMed Web of Science ®Google Scholar
• Mitchell MP, Sharma P. The use of surgery and radiotherapy as treatment of regional nodes in breast cancer patients. Oncology. 2018;32(6):e52–e64.
   PubMed Web of Science ®Google Scholar
• Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res. 2015;9:BCBCR–S29420.
   Google Scholar
• Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol. 2012;4(4):195–210. doi:10.1177/1758834012444711
   PubMed Web of Science ®Google Scholar
• Shang M, Chang C, Pei Y, Guan Y, Chang J, Li H. Potential management of circulating tumor DNA as a biomarker in triple-negative breast cancer. J Cancer. 2018;9(24):4627. doi:10.7150/jca.28458
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI45014
   PubMed Web of Science ®Google Scholar
• Barton VN, D’Amato NC, Gordon MA, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015;14(3):769–778. doi:10.1158/1535-7163.MCT-14-0926
   PubMed Web of Science ®Google Scholar
• Yan M, Li X, Tong D, et al. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncol Rep. 2016;36(1):65–71. doi:10.3892/or.2016.4767
   PubMed Web of Science ®Google Scholar
• Wu Y-M, Chen Z-J, Jiang G-M, et al. Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways. Oncotarget. 2016;7(11):12568. doi:10.18632/oncotarget.7276
   PubMedGoogle Scholar
• Maniscalco L, Millán Y, Iussich S, et al. Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. BMC Vet Res. 2013;9(1):1–9. doi:10.1186/1746-6148-9-80
   PubMed Web of Science ®Google Scholar
• Kim J-Y, Jung HH, Ahn S, et al. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep. 2016;6(1):1–11. doi:10.1038/s41598-016-0001-8
   PubMed Web of Science ®Google Scholar
• Huang L, Liu Z, Chen S, Liu Y, Shao Z. A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index. PLoS One. 2013;8(12):e83081. doi:10.1371/journal.pone.0083081
   PubMed Web of Science ®Google Scholar
• Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol. 2009;39(4):217–224. doi:10.1093/jjco/hyp007
   PubMed Web of Science ®Google Scholar
• Rampurwala M, Wisinski KB, O’Regan R. Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol. 2016;14(3):186.
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Grellety T, Tredan O, et al. A Phase II trial of Abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27(5):812–818. doi:10.1093/annonc/mdw067
   PubMed Web of Science ®Google Scholar
• Traina TA, Miller K, Yardley DA, et al. Results from a Phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Am Soc Clin Oncol. 2015. doi:10.1200/jco.2015.33.15_suppl.1003
   PubMed Web of Science ®Google Scholar
• Parker JS, Peterson AC, Tudor IC, Hoffman J, Uppal H. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. Am Soc Clin Oncol. 2015. doi:10.1200/jco.2015.33.15_suppl.1083
   PubMed Web of Science ®Google Scholar
• Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. Onco Targets Ther. 2017;10:4675. doi:10.2147/OTT.S126051
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. doi:10.1371/journal.pone.0157368
   PubMed Web of Science ®Google Scholar
• Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18(2):123. doi:10.1634/theoncologist.2012-0397
   PubMed Web of Science ®Google Scholar
• Ring BZ, Hout DR, Morris SW, et al. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer. 2016;16(1):1–8.
   Google Scholar
• Zhu A, Li Y, Song W, et al. Antiproliferative effect of androgen receptor inhibition in mesenchymal stem-like triple-negative breast cancer. Cell Physiol Biochem. 2016;38(3):1003–1014. doi:10.1159/000443052
   PubMed Web of Science ®Google Scholar
• Caiazza F, Murray A, Madden SF, et al. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. Endocr Relat Cancer. 2016;23(4):323–334. doi:10.1530/ERC-16-0068
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin Med Insights Oncol. 2016;10:CMO–S34540.
   Google Scholar
• Wang J, Chen H, Chen X, Lin H. Expression of tumor-related macrophages and cytokines after surgery of triple-negative breast cancer patients and its implications. Med Sci Mon. 2016;22:115. doi:10.12659/MSM.895386
   PubMed Web of Science ®Google Scholar
• Qiao Y, He H, Jonsson P, Sinha I, Zhao C, Dahlman-Wright K. AP-1 is a key regulator of proinflammatory cytokine TNFα-mediated triple-negative breast cancer progression. J Biol Chem. 2016;291(10):5068–5079. doi:10.1074/jbc.M115.702571
   PubMed Web of Science ®Google Scholar
• Browne G, Dragon JA, Hong D, et al. MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumor Biol. 2016;37(7):8825–8839. doi:10.1007/s13277-015-4710-6
   PubMedGoogle Scholar
• Adams BD, Wali VB, Cheng CJ, et al. miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. Cancer Res. 2016;76(4):927–939. doi:10.1158/0008-5472.CAN-15-2321
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261–1274. doi:10.1016/j.cell.2007.06.009
   PubMed Web of Science ®Google Scholar
• Chen Y-J, Yeh M-H, Yu M-C, et al. Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Res. 2013;15(6):1–14. doi:10.1186/bcr3575
   Web of Science ®Google Scholar
• Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Adv Exp Med Biol. 2006;587:309–327.
   PubMedGoogle Scholar
• Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–466. doi:10.1038/nature02924
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Mayo MW, Baldwin AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274(5288):784–787. doi:10.1126/science.274.5288.784
   PubMed Web of Science ®Google Scholar
• Phan B, Majid S, Ursu S, et al. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer. Oncotarget. 2016;7(15):19519. doi:10.18632/oncotarget.6961
   PubMedGoogle Scholar
• Zhang H, Cohen AL, Krishnakumar S, et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 2014;16(2):1–16. doi:10.1186/bcr3640
   Web of Science ®Google Scholar
• Singh JC, Novik Y, Stein S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res. 2014;16(2):1–8. doi:10.1186/bcr3634
   Web of Science ®Google Scholar
• Moestue SA, Dam CG, Gorad SS, et al. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res. 2013;15(1):1–18. doi:10.1186/bcr3391
   Web of Science ®Google Scholar
• Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. Clin Oncol. 2009;27(27):4536–4541.
   Web of Science ®Google Scholar
• Hart S, Novotny-Diermayr V, Goh KC, et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013;12(2):151–161. doi:10.1158/1535-7163.MCT-12-0466
   PubMed Web of Science ®Google Scholar
• Liang DH, Choi DS, Ensor JE, Kaipparettu BA, Bass BL, Chang JC. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Lett. 2016;376(2):249–258. doi:10.1016/j.canlet.2016.04.002
   PubMed Web of Science ®Google Scholar
• Oualla K, El-Zawahry HM, Arun B, et al. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol. 2017;9(7):493–511. doi:10.1177/1758834017711380
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes. J Pathol. 2014;232(2):142–150. doi:10.1002/path.4280
   PubMed Web of Science ®Google Scholar
• Yao H, He G, Yan S, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913. doi:10.18632/oncotarget.12284
   PubMedGoogle Scholar